Study of combination therapy for locally advanced anal cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a combination of new and existing drugs, followed by chemoradiotherapy with immunotherapy, for people with locally advanced squamous cell carcinoma of the anal canal. It aims to see if this approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with locally advanced anal cancer that has not spread to distant organs.
- You are generally able to perform daily activities (ECOG score 0 or 1).
- Your tumor tests positive for a certain protein called EGFR (score of 1+ or higher).
- You have at least one measurable tumor that can be tracked during the study.
- You have adequate organ function (kidney, liver, bone marrow, heart) and are willing to use contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial provides access to a combination of an immunotherapy drug (retifanlimab) with two chemotherapy drugs (carboplatin and paclitaxel) for people with a certain type of anal cancer that has spread or cannot be removed. The goal is to see if this treatment can help control the cancer.
This study tests a combination of chemotherapy, radiation therapy, and an immunotherapy drug (anti-PD-1 antibody) for anal squamous cell cancer. The trial enrolls patients at different stages of disease to see if adding immunotherapy improves outcomes.
This Phase 2 trial studies a combination of immunotherapy (spartalizumab), chemotherapy (mDCF includes docetaxel), and radiation to treat metastatic or returning anal squamous cell cancer. It may help shrink tumors and improve outcomes compared with standard approaches, but eligibility is strict to keep participants safe.
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for people with advanced anal cancer that has spread or come back. The goal is to see if this combination can help shrink or control the cancer.
This trial tests if giving chemotherapy before standard chemoradiation works better than standard chemoradiation alone for people with locally advanced anal cancer that has not spread. It aims to improve treatment outcomes.
This trial tests an adaptive, image-guided radiation plan for anal canal squamous-type cancers. It may help deliver effective treatment while adjusting the radiation based on how your body and tumor respond.
Hear when a new Squamous Cell Carcinoma of the Anal Canal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.